Publications

  1. Vo, C.D.*, Shebert, H.L.*, Zikovich, S.*, Dryer, R.A.*, Huang, T.P.*, Moran, L.J.*, Cho, J.*, Wassarman, D.R.*, Falahee, B.E.*, Young, P.D.*, Gu, G.H.*, Heinl, J.F.*, Hammond, J.W.*, Jackvony, T.N.*, Frederick, T.E., Blair, J.A. Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases. Bioorganic & Medicinal Chemistry Letters 2017, 27, 5235–5244. * Williams College student collaborators. [pubmed]
  2. Mann, T.H., Childers, W.S., Blair, J.A., Eckart, M.R., Shapiro, L. A cell cycle kinase with tandem sensory PAS domains integrates cell fate cues. Nature Communications 2016, 7, 11454. [pubmed]
  3. Stott, K.V., Wood, S.M., Blair, J.A., Nguyen, B.T., Herrera, A., Mora, Y.P., Cuajungco, M.P., Murray, S.R. (p)ppGpp modulates cell size and the initiation of DNA replication in Caulobacter crescentus in response to a block in lipid biosynthesis. Microbiology 2015161, 553–564. [pubmed]
  4. Childers, W.S., Xu, Q., Mann, T.H., Irimpan I.M., Blair, J.A., Deacon, A.M., Shapiro L. Cell fate regulation governed by a repurposed bacterial histidine kinase. PLoS Biology 201412, e1001979. [pubmed]
  5. Blair, J. A.; Xu, Q.; Childers, W. S.; Mathews, I. I.; Kern, J. W.; Eckart, M.; Deacon, A. M.; Shapiro, L. Branched signal wiring of an essential bacterial cell-cycle phosphotransfer protein. Structure 2013, 21, 1590–1601. [pubmed]
  6. Barkovich, K. J.; Hariono, S.; Garske, A. L.; Zhang, J.; Blair, J. A.; Fan, Q. W.; Shokat, K. M.; Nicolaides, T.; Weiss, W. A. Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers. Cancer Discov 2012, 2, 450–457. [pubmed]
  7. Amin, D. N.; Sergina, N. V.; Ahuja, D.; McMahon, M.; Blair, J. A.; Wang, D.; Hann, B.; Koch, K. M.; Shokat, K. M.; Moasser, M. M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2010, 2, 16ra7. [pubmed]
  8. Wong, C. H.; Baehner, F. L.; Spassov, D. S.; Ahuja, D.; Wang, D.; Hann, B.; Blair, J.; Shokat, K. M.; Welm, A. L.; Moasser, M. M. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res 2009, 15, 2311–2322. [pubmed]
  9. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008, 4, 691–699. [pubmed]
  10. Blair, J. A.; Rauh, D.; Kung, C.; Yun, C.-H.; Fan, Q.-W.; Rode, H.; Zhang, C.; Eck, M. J.; Weiss, W. A.; Shokat, K. M. Structure-guided development of affnity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 2007, 3, 229–238. [pubmed]
  11. Sergina, N. V.; Rausch, M.; Wang, D.; Blair, J.; Hann, B.; Shokat, K. M.; Moasser, M. M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445, 437–441. [pubmed]